Posts by Mourabit Halima

Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute liver function deterioration based on chronic liver disease, accompanied by high mortality rates of liver and extra-hepatic organ failure. The short-term mortality rate of comprehensive internal medicine treatment ranges from 50% to 90%. Due to its high mortality and complex pathogenesis, research and treatment strategies for ACLF are particularly crucial. From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy, where Professor Jun Li 's team from the First Affiliated Hospital of Zhejiang University School of Medicine presented five research findings related to ACLF. Hepatology Digest invited Professor Jun Li to introduce the highlights and significance of these studies, share his conference insights, and discuss the future development of the ACLF field. The following is the interview transcript.

From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During this event, the team led by Professor Shuangsuo Dang from the Department of Infectious Diseases at the Second Affiliated Hospital of Xi’an Jiaotong University presented three significant clinical and basic research findings: real-world antiviral treatment for chronic hepatitis B (CHB), mechanisms and treatment of metabolic-associated fatty liver disease (MAFLD), and risk factors and mechanisms of hepatocellular carcinoma (HCC). This report covers these studies for our readers.

Editor's Note: From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. Over 7,000 hepatology experts from around the world gathered for this academic event. On the first day, the conference focused on various fields including chronic hepatitis B, cirrhosis, and portal hypertension. Hepatology Digest invited two young experts from the Chinese University of Hong Kong, Professor Terry Yip and Dr. Jimmy Che-To Lai, to share their insights and experiences.

Liver biopsy is the "gold standard" for diagnosing liver fibrosis, but due to its high cost, invasive nature, and other disadvantages, it is not widely used. Currently, various non-invasive tests (NITs) based on serum biochemical indicators and/or imaging have been developed to evaluate liver stiffness and diagnose liver fibrosis, aiming to identify high-risk populations early for timely intervention and management. However, the diagnostic performance of various NITs varies, and some diagnostic devices are not easily accessible. Finding an NIT with high accuracy and accessibility is a clinical challenge.

On June 7, 2024, at 5:30 PM in Milan, Italy, the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) jointly released the latest Clinical Practice Guidelines for the management of Metabolic Associated Fatty Liver Disease (MASLD) at the EASL 2024 Annual Meeting. The guidelines cover a wide range of topics from the use of non-invasive diagnostic tools to treatment strategies, emphasizing the importance of treating obesity and diabetes and multidisciplinary collaboration in the management of MASLD. These guidelines have been simultaneously published online in the official journals of EASL, EASD, and EASO, such as the Journal of Hepatology.

From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting took place in the beautiful city of Milan, Italy. Over 7,000 liver disease experts from around the world attended this top-tier academic event. The conference covered a range of diseases including viral hepatitis, metabolic associated fatty liver disease, cirrhosis, liver cancer, and liver failure, presenting the latest clinical research findings in the field. Among the participants, Professor Rui Huang's team from Peking University People's Hospital had two studies accepted for presentation as poster sessions. Their research found that the ratio of visceral fat area to subcutaneous fat area (VSR), sarcopenia, and muscle fat infiltration are independent predictors of liver-related mortality in cirrhosis patients. Additionally, loss of skeletal muscle mass is crucial in predicting liver-related mortality in cirrhosis patients. These findings suggest that actively managing body composition, particularly skeletal muscle mass and visceral and subcutaneous fat content, can help improve prognosis in cirrhosis patients.